StockData
Summit Therapeutics Inc. logo

Summit Therapeutics Inc. (SMMT) stock

SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$10.57+0.07 (+0.67%)

Close on Nov 19, 2026Market cap $8.43BP/E –Yield –

Summit Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Summit Therapeutics's price to sales ratio was 395.2× on Apr 28, 2023, against 4.6× a year earlier. Over the last 4 years it ranged from 0.4× to 395.2×, with a median of 1.9×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2023Apr 28, 2023395.2×+226.8
2022Nov 30, 2022168.5×+163.9
2021Dec 31, 20214.6×+3.2
2020Dec 31, 20201.4×+0.9
2019Dec 31, 20190.5×–

More Summit Therapeutics figures

See a number that looks wrong?